Nuvalent (NUVL) Profit After Tax (2020 - 2026)
Nuvalent's (NUVL) quarterly Profit After Tax came in at -$113.0 million in Q1 2026, down 33.58% YoY from -$170.1 million in Q1 2025, and up 6.74% on a QoQ basis from -$121.2 million in Q4 2025.
Nuvalent (NUVL) Profit After Tax (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Profit After Tax data on file, last reported at -$113.0 million in Q1 2026.
- Quarterly Profit After Tax fell 33.58% year-over-year to -$113.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$455.2 million (down 50.64% YoY) and the FY2025 annual result came in at -$425.4 million, down 63.14% from the prior year.
- Profit After Tax rose to -$113.0 million in Q1 2026, from -$121.2 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$17.5 million in Q1 2022 to a low of -$121.4 million in Q3 2025.
- A 5-year average of -$59.4 million and a median of -$44.5 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax slumped 158.64% — and 2026, when it tumbled 33.58%.
- Tracing NUVL's Profit After Tax over 5 years: stood at -$26.1 million in 2022, then plunged by 46.58% to -$38.3 million in 2023, then tumbled by 98.75% to -$76.1 million in 2024, then slumped by 59.2% to -$121.2 million in 2025, then climbed by 6.74% to -$113.0 million in 2026.
- The last three Profit After Tax figures came in at -$113.0 million (Q1 2026), -$121.2 million (Q4 2025), and -$121.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -112.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112.99 Mn |
| Dec 31, 2025 | -121.16 Mn |
| Sep 30, 2025 | -121.43 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -76.11 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -26.12 Mn |
| Sep 30, 2022 | -19.45 Mn |
| Jun 30, 2022 | -18.47 Mn |
| Mar 31, 2022 | -17.55 Mn |
| Dec 31, 2021 | -17.23 Mn |
| Sep 30, 2021 | -12.45 Mn |
| Jun 30, 2021 | -9.84 Mn |